NCT06421948View on ClinicalTrials.gov

Linperlisib Combined With Chidamide in Patients With PTCL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Linperlisib and chidamide

A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.

DRUG

cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone

A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.

Trial Locations (1)

450008

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Yanyan Liu

OTHER_GOV